Published in Vasc Health Risk Manag on January 01, 2009
Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients (RAND) | NCT01195818
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol (2010) 0.94
Optimizing blood pressure control in patients with chronic kidney disease. Proc (Bayl Univ Med Cent) (2010) 0.83
Emerging drug combinations to optimize renovascular protection and blood pressure goals. Int J Nephrol Renovasc Dis (2012) 0.76
Correlation between Diastolic Function and Endothelial Function in Patients with Type 2 Diabetes and Hypertension. Open Cardiovasc Med J (2016) 0.75
Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient. Ther Adv Endocrinol Metab (2010) 0.75
Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol (2017) 0.75
Efficacy and Tolerability of Antihypertensive Drugs in Diabetic and Nondiabetic Patients. J Pharm Bioallied Sci (2017) 0.75
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Standards of medical care in diabetes--2008. Diabetes Care (2008) 17.23
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care (1991) 9.95
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) 8.55
Vascular risk factors and diabetic neuropathy. N Engl J Med (2005) 7.69
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med (1998) 7.18
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet (2007) 6.80
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Diabetes, hypertension, and cardiovascular disease: an update. Hypertension (2001) 4.62
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension (2006) 3.89
Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol (1988) 3.54
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care (1998) 3.52
Renin-angiotensin system and cardiovascular risk. Lancet (2007) 3.47
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med (2005) 3.44
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med (1999) 3.43
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000) 3.37
Diabetic retinopathy. Diabetes Care (2004) 2.97
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 2.96
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension (2008) 2.83
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 2.81
A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med (1989) 2.79
Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol (2005) 2.39
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int (2008) 2.26
Changes in serum potassium mediate thiazide-induced diabetes. Hypertension (2008) 2.09
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst (2007) 1.98
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care (2006) 1.97
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension (2004) 1.90
Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J (2003) 1.82
Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med (1996) 1.79
Hypertension management in adults with diabetes. Diabetes Care (2004) 1.79
Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med (2007) 1.77
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med (2002) 1.73
Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension (2001) 1.70
Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int (1989) 1.65
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens (2008) 1.61
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care (2005) 1.55
Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J (1995) 1.51
Renal dysfunction complicating the treatment of hypertension. N Engl J Med (2002) 1.47
Implications for cost-effectiveness. Combination therapy for systemic hypertension. Am J Cardiol (1995) 1.46
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet Med (1999) 1.42
Diuretic complications. Am J Med Sci (2000) 1.42
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant (1998) 1.42
Facing the diabetes epidemic--mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med (2006) 1.38
Ca2+ channel subtypes and pharmacology in the kidney. Circ Res (2007) 1.38
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation (2004) 1.33
An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol (2006) 1.21
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol (2004) 1.19
Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol (1985) 1.17
Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest (1988) 1.16
Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ (1992) 1.15
Managing hypertension using combination therapy. Am Fam Physician (2008) 1.13
Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med (2008) 1.08
A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol (1999) 1.07
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens (1998) 1.06
The renin response to diuretic therapyl A limitation of antihypertensive potential. Circ Res (1978) 0.99
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int (1998) 0.99
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension (2003) 0.98
Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs (2006) 0.97
Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens (2002) 0.96
Patient perspectives on multiple medications versus combined pills: a qualitative study. QJM (2005) 0.95
Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest (1987) 0.95
Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) (2005) 0.95
The CARI guidelines. Prevention of progression of kidney disease. Nephrology (Carlton) (2006) 0.92
Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension. Am J Nephrol (2003) 0.92
Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab (2003) 0.92
Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens (2000) 0.92
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) (2003) 0.92
Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol (2008) 0.91
Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs (2005) 0.91
Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol (2006) 0.90
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag (2008) 0.90
Racial differences in trends of end-stage renal disease, by primary diagnosis--United States, 1994-2004. MMWR Morb Mortal Wkly Rep (2007) 0.90
Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol (1985) 0.89
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94
Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension (2012) 5.60
Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 4.38
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens (2011) 3.50
Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens (2005) 3.15
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension (2007) 2.63
Short- and long-term incidence of stroke in white-coat hypertension. Hypertension (2004) 2.58
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension (2005) 2.54
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension (2012) 2.02
Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens (2007) 1.97
Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis (2010) 1.81
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation (2011) 1.77
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Sexual dysfunction in women with ESRD requiring hemodialysis. Clin J Am Soc Nephrol (2012) 1.56
Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens (2004) 1.54
Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens (2006) 1.51
Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J (2005) 1.47
Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J (2009) 1.47
Are observational studies more informative than randomized controlled trials in hypertension? Pro side of the argument. Hypertension (2013) 1.44
Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens (2007) 1.43
Early invasive versus selectively invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: impact of age. Catheter Cardiovasc Interv (2014) 1.43
Meta-Analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol (2004) 1.42
Atrial fibrillation in hypertension: predictors and outcome. Hypertension (2003) 1.40
Blood pressure lowering in the oldest old. J Hypertens (2010) 1.40
[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39
Reducing blood pressure in people of different ages. BMJ (2008) 1.39
Multivariable analysis in cerebrovascular research: practical notes for the clinician. Cerebrovasc Dis (2013) 1.38
The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens (2009) 1.38
Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol (2002) 1.31
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol (2012) 1.28
Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study. Am J Hypertens (2005) 1.23
Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens (2003) 1.16
Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension (2009) 1.16
Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens (2010) 1.12
Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension (2002) 1.12
The first statement of the Working Group on Electrocardiographic Diagnosis of Left Ventricular Hypertrophy. J Electrocardiol (2010) 1.12
Ambulatory blood pressure for cardiovascular risk stratification. Circulation (2007) 1.10
Clinical usefulness of ambulatory blood pressure monitoring. J Am Soc Nephrol (2004) 1.08
Contribution of the ABP-International study to the definition of night-time tachycardia. J Hypertens (2014) 1.07
Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens (2010) 0.98
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens (2008) 0.97
Testis-sparing surgery for the conservative management of small testicular masses: an update. Anticancer Res (2013) 0.97
Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol (2002) 0.97
Association between periodontal disease and left ventricle mass in essential hypertension. Hypertension (2003) 0.96
Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol (2007) 0.96
Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens (2014) 0.96
Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. Nephrol Dial Transplant (2013) 0.95
Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 0.94
[The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the weapons are ready]. Rev Esp Cardiol (2003) 0.93
Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. Eur J Cardiovasc Prev Rehabil (2011) 0.91
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag (2008) 0.90
Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens (2003) 0.90
New-onset diabetes, antihypertensive treatment, and outcome. Hypertension (2007) 0.90
Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens (2002) 0.90
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant (2011) 0.90
Validation of the A&D UA-774 (UA-767Plus) device for self-measurement of blood pressure. Blood Press Monit (2004) 0.89
Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep (2012) 0.88
Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis (2010) 0.88
Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep (2012) 0.87
White-coat hypertension in adults. Blood Press Monit (2005) 0.86
Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol (2013) 0.86
Sex-related penile fracture with complete urethral rupture: A case report and review of the literature. Arch Ital Urol Androl (2015) 0.85
Is the definition of daytime and nighttime blood pressure prognostically relevant? Blood Press Monit (2008) 0.85
Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol (2011) 0.85
Are diabetes, hypertension, and obesity independent risk factors for endometrial polyps? J Minim Invasive Gynecol (2009) 0.84
ß-Blockers reduce mortality in patients undergoing high-risk non-cardiac surgery. Am J Cardiovasc Drugs (2010) 0.84
New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Diabetes Rev (2010) 0.84
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther (2004) 0.83
Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis. Am J Kidney Dis (2013) 0.83
Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study. Nephrol Dial Transplant (2011) 0.83
Methods of measurements: home and ambulatory blood pressure monitoring. Blood Press Monit (2010) 0.83
Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension (2013) 0.83
Epithelioid sarcoma of the penis: a case report. J Sex Med (2012) 0.83